Splitomicin is a small-molecule inhibitor that binds to the protein SIRT2 and inhibits its NAD+-dependent HDAC activity. HDAC inhibitors focus on HDAC enzymes, hindering the growth of cancer cells and triggering apoptosis, the programmed death of cancer cells. Reagent grade, for research purpose.
Usually ships within 24 hours.